Prot#VK2809-202: A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of VK2809 Administered for 52 Weeks Followed by a 4-Week Off-Drug Phase in Subjects with Biopsy Proven Non-Alcoh

  • Rinella, Mary Eugenia (PD/PI)

Project: Research project

Project Details

Effective start/end date3/4/203/4/23


  • Covance Inc. (Prot#VK2809-202 // Prot#VK2809-202)
  • Viking Therapeutics, Inc. (Prot#VK2809-202 // Prot#VK2809-202)